On March 30, 2020 Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, reported that its Chief Executive Officer, Bill Enright, will present an update on the Company’s progress at the upcoming Solebury Trout Virtual Investor Conference (Press release, Vaccitech, MAR 30, 2020, View Source [SID1234556135]). The presentation will include recent encouraging Phase 2 efficacy data for Vaccitech’s prostate cancer therapeutic combined with an anti-PD-1 checkpoint inhibitor in metastatic castration resistant prostate cancer patients. The presentation will also outline ongoing COVID-19 vaccine efforts using Vaccitech’s proprietary ChAdOx1 vector.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vaccitech is one of the few companies in the world that has data in humans demonstrating neutralizing antibodies against a coronavirus with its MERS (Middle Eastern Respiratory Syndrome) vaccine candidate.
Date of presentation: Tuesday, 31 Tuesday, 2020
Time: 10:00 am – 10:30 am ET